Their data showed the enhanced effect of slower-metabolizing CYP2C9 variants on the chemopreventive activity of ibuprofen against CRC, and CYP variants were more effective in individuals with wild-type rather than variant UGT1A6[25]. The gene discussed is CYP2C9; the disease is colorectal carcinoma.